Introduction
============

In Archaea and Bacteria, the mRNA Shine-Dalgarno sequence promotes binding of the ribosome to mRNA and thus translation initiates ([@B117]). Contrary to that, the majority of eukaryotic precursor mRNAs harbor a 5′ end cap, a 7 methylguanosine triphosphate (m7GpppG) structure, which serves as a docking point for eukaryotic translation initiation factors (eIFs) ([@B36]; [@B115]; [@B35]; [@B122]). eIF4E directly binds the mRNA 5′ cap ([@B122]) and interacts with the scaffolding protein eIF4G, which in turn binds the helicase eIF4A to form the eIF4F complex and allow the recruitment of ribosomes to initiate the predominant form of eukaryotic translation: cap-dependent translation ([@B40]). eIF4G provides the backbone of the eIF4F complex. In addition, it helps to circularize mRNAs through its interaction with poly(A) binding proteins (PABPs) and provides a binding site for other regulatory factors, such as MAP kinase-interacting serine/threonine-protein kinases 1/2 (MNK1/2) and eukaryotic Initiation Factor 3 (eIF3). The eIF4A helicase unwinds secondary structures present in the mRNA 5′ Untranslated Regions (UTRs) to facilitate translation. eIF4A helicase activity is promoted by eIF4G and eIF4B ([@B40]), as well as eIF4E ([@B33]). Cap-dependent translation is responsible for the bulk of protein synthesis in eukaryotic cells, and is the rate limiting step in protein synthesis. Crucially, eIF4E and the eIF4F complex carry a well-conserved function in eukaryotes, where they preferentially regulate the synthesis of a subset of proteins, by controlling mRNA translation initiation ([@B99]; [@B120], [@B121]; [@B49]). Thus, the term "eIF4E/eIF4F-sensitive" mRNAs has emerged ([@B49]). Consequently, eIF4E activity is tightly regulated by a variety of factors such as hormones, growth factors, cytokines and other extracellular stimuli, which converge on two major signaling cascades: MAPK/ERK and PI3K/mTOR pathways ([@B61]; [@B114]; Figure [1](#F1){ref-type="fig"}).
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The PI3K/mTOR pathway regulates eIF4E function via the action of eIF4E-binding proteins (4E-BPs) ([@B98]). 4E-BPs compete with eIF4G for binding on the dorsal surface of eIF4E, hence disrupting the formation of the eIF4F complex ([@B98]). Hypo-phosphorylated 4E-BPs have a higher affinity for eIF4E and thus repress translation initiation ([@B41]). Conversely, activation of PI3K/mTOR signaling leading to downstream phosphorylation of 4E-BPs by mTORC1, triggers the release of 4E-BPs from eIF4E. As a result, the availability of eIF4E for initiation increases ([@B47]; [@B104]).

Activation of MAPK/ERK pathway leads to phosphorylation of eIF4E at the Serine 209 residue by MNK1/2 ([@B60]; [@B130]). MNK1/2 are recruited to the eIF4F complex by binding to the c-terminal domain of eIF4G, where they promote the phosphorylation of eIF4E ([@B101]; [@B118]). While two studies suggested that eIF4E phosphorylation is either not required for translation ([@B84]) or that it decreases cap-dependent translation ([@B71]), the majority of the literature suggests that eIF4E phosphorylation promotes initiation ([@B101]; [@B73]; [@B95]; [@B13]). Moreover, several studies have identified phospho-eIF4E-sensitive mRNAs in cancer ([@B34]; [@B45]; [@B72]; [@B106]) and in the nervous system ([@B42]; [@B15]; [@B7]). eIF4F complex formation is also affected by sequestering eIF4E in a repressive complex with the Fragile X Mental Retardation Protein (FMRP) and the Cytoplasmic FMRP Interacting Protein (CYFIP1) ([@B91]). The eIF4E-CYFIP complex is sensitive to MNK1/2 activity and precludes eIF4E-eIF4G binding, thus hindering translation initiation ([@B91]; [@B95]; [@B39]; [@B13]).

eIF4E-dependent translational control is linked to several cellular processes, including cell cycle progression, cell survival, cell motility and tumorigenesis ([@B103]; [@B82]; [@B125]), as well as inflammation, immunity and viral infection ([@B58]; [@B50]). Nevertheless, a growing body of evidence indicates eIF4E-dependent translation is important for neuronal cell function and implicates its aberrant function in nervous system disorders (Figure [2](#F2){ref-type="fig"}), such as neurodevelopmental and neuropsychiatric conditions ([@B20]; [@B112]; [@B123]).
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Autism Spectrum Disorders (ASD) and Fragile X Syndrome (FXS)
============================================================

Autism Spectrum Disorders are a group of heterogeneous neurodevelopmental conditions characterized by persistent deficits in sociability, impaired communication, and the presence of restricted or repetitive stereotypical behaviors ([@B29]). ASDs are amongst the most common neurodevelopmental disorders, with an estimated prevalence of 16:1000 in children aged 8 years in the United States and high heritability ([@B109]; [@B8]). ASDs have been linked to a variety of genetic mutations and risk factors, including genetic variants in conditions such as Rett syndrome, Tuberous Sclerosis and FXS ([@B16]). FXS is one of the most common inherited forms of intellectual disability and is the leading genetic cause of ASDs ([@B37]; [@B83]). FXS is caused by a mutation (CGG nucleotide repeats) in the 5′ UTR of the *FMR1* gene, leading to transcriptional silencing of *FMR1* and subsequent loss of FMRP expression ([@B113]). FMRP is a translational repressor, thus its loss engenders an across the board increase in protein synthesis ([@B74]). Protein synthesis-linked hyperactivation of type I metabotropic glutamate receptors (mGluRs), leading to synaptic dysfunction, constitutes the predominant mechanistic theory aiming to explain the diverse pathophysiology of FXS ([@B9]).

Likewise, ASD is believed to arise from common downstream defects in synaptic function and brain connectivity ([@B4]). A leading hypothesis posits that downstream defects in mRNA translation lead to aberrant local protein synthesis, which results in altered synaptic development and plasticity ([@B66]; [@B44]). In accordance, patients and animal models of ASD and FXS show widespread alterations in synaptic plasticity and dysregulated mRNA translation ([@B66]; [@B62]; [@B19]; [@B21]). Altered translation in ASD and FXS results not only from mutations in genes that directly impact on translational control mechanisms, but also from altered signaling, upstream of translation (MAPK/ERK and PI3K/mTOR) ([@B20]). A pivotal convergence point of these pathways is the control of cap-dependent translation, particularly through the function of the eIF4F complex.

Abnormalities in the *EIF4E* locus have been identified in genetic studies of autistic patients ([@B136]; [@B92]; [@B132]). Moreover, a comparison of gene-expression in rodent models of maternal immune activation (MIA) with ASD patient cortical gene-expression revealed a strong involvement of the Tsc2/mTOR/eIF4E axis ([@B76]). MIA during the first trimester of pregnancy increases the risk for ASD most likely by affecting fetal brain development. Notwithstanding some epidemiological evidence, there is no compelling, direct link of *EIF4E* to ASDs. Nonetheless, several reports from animal models of ASD provide strong evidence for a key role of *Eif4e* in ASD. Deletion of *Eif4ebp2* (the predominant 4E-BP in the brain) or overexpression of *Eif4e* in mice lead to altered synaptic excitation/inhibition balance and altered behaviors, such as social interaction deficits, altered ultrasonic vocalizations, and repetitive/stereotyped behaviors ([@B43]; [@B111]). Molecular, electrophysiological and behavioral defects in mice, which are reminiscent of ASD phenotypes diagnosed in patients, could be normalized by inhibition of cap-dependent translation using 4EGI-1 ([@B43]; [@B111]), a small molecule developed as an eIF4E-eIF4G interaction inhibitor ([@B87]). Recent work revealed that type I mGluR agonists, which were proposed as FXS therapeutics, also rescue phenotypes reminiscent of ASD in *Eif4ebp2* knockout mice ([@B6]). Furthermore, 4EGI-1 has shown beneficial effects in *Fmr1*^-/y^ mice, a model of FXS, where it reversed contextual memory deficits and normalized altered dendritic morphology, dysregulated actin dynamics and exaggerated mGluR-dependent LTD ([@B110]). Interestingly, crossing *Fmr1*^-/y^ mice with *Eif4e* overexpressing mice engenders cognitive impairments in addition to ASD-like phenotypes ([@B53]).

Regulation of eIF4E by phosphorylation is associated with FXS. Patients and animal models of FXS show increased levels of phosphorylated eIF4E ([@B51]; [@B42]; [@B119]). Moreover, genetic deletion of the MNK1/2 kinases, which phosphorylate eIF4E, administration of the MNK1/2 inhibitor cercosporamide, or substitution of the eIF4E phosphorylation site for a non-phosphorylatable residue (*Eif4e*^ki/ki^ mice; Ser209Ala), ameliorated FXS phenotypes in *Fmr1*^-/y^ mice ([@B42]).

In addition to eIF4E phosphorylation, a new translational control mechanism was found where FMRP interacts with eIF4E through CYFIP1 to prevent eIF4E-eIF4G binding, thereby hindering translation initiation ([@B91]). The FMRP-CYFIP1-eIF4E complex is present in dendritic spines and actively participates in the local control of protein synthesis during synaptic activity. Synaptic activation by BDNF or mGluR stimulates the release of FMRP and CYFIP1 from eIF4E and promotes local translation ([@B91]; [@B39]). In fact, the levels of CYFIP1 have been shown to influence the maturation of dendritic spines ([@B97]; [@B94]), whereas *Cyfip1*^+/-^ mice show some phenotypes similar to *Fmr1*^-/y^ mice, such as exaggerated mGluR-LTD ([@B11]).

One avenue through which aberrant eIF4E-dependent translation may lead to the manifestation of ASDs is through the translational control of specific subsets of mRNAs. eIF4E was shown to regulate the translation of mRNAs with 5′ UTRs that are highly structured ([@B33]; [@B49]) or that contain CERT (cytosine-enriched regulator of translation) motifs ([@B129]). Furthermore, phosphorylation of eIF4E has been proposed to affect the translation of mRNAs containing 3′ GAIT (interferon (IFN)-γ-activated inhibitor of translation) elements ([@B7]). Subsets of mRNAs controlled by eIF4E perform a variety of functions, such as promoting tumorigenesis or participating in the control of the circadian rhythm and serotonin pathways ([@B34]; [@B15]; [@B7]). In addition, eIF4E-sensitive mRNAs encode scaffolding proteins such as neuroligins ([@B43]; [@B100]; [@B107]) and extracellular matrix components ([@B42]; [@B7]). Mutations in several neuroligin isoforms are present in ASD patients ([@B57]). In addition, overproduction of neuroligins was shown to modulate synaptic function and behavior in animal models of ASD and FXS ([@B48]; [@B22]; [@B23]; [@B43]). Extracellular matrix metalloproteinase 9 (MMP-9) regulates spine morphology, synaptic plasticity, learning and memory ([@B52]), and is implicated in phenotypes in rodent models of ASD and FXS ([@B10]; [@B108]; [@B28]; [@B119]). Translation of MMP-9 is stimulated by eIF4E phosphorylation, the levels of which are increased in FXS patients and *Fmr1*^-/y^ mice ([@B51]; [@B42]; [@B119]). In addition, modulation of MMP-9 expression in rodents modulates FXS phenotypes associated with increased eIF4E phosphorylation ([@B42]; [@B38]). Finally, a recent study proposes a novel mechanism, whereby eIF4E is required for repeat-associated non-AUG (RAN) translation of the *FMR1* gene ([@B65]). CGG repeats in the *FMR1* gene stimulate RAN translation, which leads to the synthesis of toxic polypeptides ([@B127]).

Apart from direct translational control, eIF4E may be linked to ASD pathophysiology via a role in early neuronal development through its interaction with the eIF4E-Transporter (4E-T) in processing bodies (P-bodies), which are cytoplasmic granules involved in mRNA degradation ([@B32]). Here, eIF4E and 4E-T cooperate to sequester and repress the translation of pro-neurogenic mRNAs, such as transcription factors and neuronal differentiation-related mRNAs ([@B135]). In addition, recent work revealed that 4E-T also binds to Pumilio2 and that this complex ensures neuronal specification of deep and superficial layer murine cortical neurons ([@B138]).

Depression and Anxiety Disorders
================================

Depressive and anxiety disorders are often comorbid and represent the most common causes of disability worldwide ([@B140]). In addition, these psychiatric conditions are commonly present in people suffering from ASDs ([@B78]). mTOR signaling is affected in patients with major depressive disorder as well as animal models of depression and anxiety ([@B59]; [@B17]; [@B54]). Furthermore, treatment with selective serotonin reuptake inhibitors or other anti-depressant drugs, such as ketamine, were shown to affect mTOR and its downstream targets p70S6K and 4E-BP1 ([@B59]; [@B96]; [@B75]; [@B141]; [@B3]). MAPK/ERK signaling is also altered in patients and animal models of depressive disorders ([@B26]; [@B102]; [@B27]). Given the convergence of these two pathways in the control of translation initiation, the question arises of how eIF4E function may affect or be affected by depression and anxiety disorders.

Two recent studies revealed that mice with defective eIF4E phosphorylation (*Mnk1/2*^-/-^ or *Eif4e*^ki/ki^ mice) show behaviors reminiscent of depression and anxiety, concomitant with increased inflammatory responses. *Mnk1/2*^-/-^ and *Eif4e*^ki/ki^ mice displayed increased immobility in the force-swimming and tail suspension tests, increased latency to feed in a novelty suppressed feeding assay, and anxiety behaviors in the open-field and elevated plus maze tests ([@B5]; [@B7]). Translational profiling in brain tissue from *Eif4e*^ki/ki^ mice revealed increased translation of genes involved in serotonin pathways concomitantly with reduced levels of serotonin in the brain ([@B7]). [@B5] further report impaired serotonin transmission in the prefrontal cortex and reduced firing of serotonergic neurons in the dorsal raphe of *Eif4e*^ki/ki^ and *Mnk1/2*^-/-^ mice. Moreover, loss of eIF4E phosphorylation resulted in elevated levels of key inflammatory cytokines, including TNFα, IFNγ, and IL-2, in addition to an exaggerated response to lipopolysaccharide-induced microglial activation and cytokine production ([@B5]; [@B7]). Interestingly, administration of a dominant negative form of TNFα rescued the behavioral and electrophysiological abnormalities in *Eif4e*^ki/ki^ mice ([@B5]).

The connection between depression and inflammation has received increased attention ([@B86]). There is an elevated comorbidity between depression and chronic inflammatory conditions ([@B1]; [@B31]), and while several studies have found increased levels of pro-inflammatory cytokines in patients with anxiety and major depressive disorder ([@B25]; [@B116]; [@B88]; [@B85]), anti-inflammatory drugs are effective in the treatment of depression ([@B90]; [@B133]). The new evidence from [@B7] suggests an important mechanism through which impaired translation control via dysregulated eIF4E phosphorylation downstream of the MAPK/ERK pathway affects the translation of specific mRNAs to directly influence the inflammatory response and impact on depression and anxiety-like behaviors. [@B7] propose that eIF4E phosphorylation may control inflammatory responses in depression by regulating binding of the 3′ UTR element (GAIT) onto the 5′ eIF4F complex in circularized pro-inflammatory mRNAs. The GAIT complex acts as a translational repression mechanism that controls the translation of pro-inflammatory mRNAs ([@B89]). Loss of eIF4E phosphorylation may decrease the affinity of the GAIT complex to eIF4F, thus allowing excessive translation of pro-inflammatory mRNAs.

Schizophrenia (SCZ)
===================

SCZ is a neuropsychiatric disorder characterized by a combination of positive, negative and cognitive symptoms, including hallucinations and delusions, apathy and social withdrawal, and attention, memory and executive thinking deficits, respectively. SCZ is a highly disabling condition, affecting around 1% of the population, and it has high heritability rates ([@B63]). The etiology of SCZ is not fully understood and is associated with a variety of genetic and environmental risk factors. Even though *DISC1* is one of the better characterized genes regarding its association with SCZ ([@B105]; [@B12]), several studies have additionally identified *de novo* copy number variants (CNVs) as conferring high risk for the development of the disease ([@B134]; [@B79]). Interestingly, these CNVs are often associated risk factors for other neurodevelopmental disorders, such as ASD, mental retardation and epilepsy ([@B126]). In addition, network analysis has suggested they affect neurodevelopmental, synaptic function and post-synaptic signaling pathways ([@B131]; [@B70]; [@B14]).

One recurrent CNV associated with SCZ, as well as with cognitive and behavioral abnormalities, is the 15q11.2 microdeletion ([@B124]; [@B69]; [@B24]). The 15q11.2 locus includes four genes -- *CYFIP1*, *TUBGCP5*, *NIPA1*, and *NIPA2*. Of particular interest is the *CYFIP1* gene, which has emerged as an important player in ASD and FXS and participates in the control of protein synthesis and dendritic spine maturation. Furthermore, CYFIP1 is also part of the WAVE regulatory complex, which is involved in the control of actin polymerization and lamellipodia formation ([@B18]; [@B2]). The functioning of this complex and of CYFIP1 contribute to the correct formation of adherens junctions and cell polarity in patient-derived induced pluripotent stem cells (iPSCs) neuroprogenitor cells ([@B137]). Other studies have used iPSCs-derived neuronal populations to address SCZ-related impairments in cell migration, cytoskeletal remodeling and protein synthesis ([@B14]; [@B128]). Interestingly, by using olfactory neurosphere-derived cells, a model that was shown to replicate some of the molecular phenotypes of SCZ ([@B77]), [@B30] identified, both at the level of the transcriptome and proteome, significant changes in signaling pathways key to the control of mRNA translation, including eIF2, eIF4 and mTOR signaling. Although the role of mTOR in SCZ has not been well established, various studies have noted the presence of altered mTOR signaling, particularly in the context of *DISC1* animal models ([@B68]; [@B139]; [@B46]). Exploring the relationship between mTOR and SCZ will be particularly interesting in terms of its connection to eIF4E, given the ability of this initiation factor to interact with CYFIP1 and to influence crucial mechanisms to SCZ, such as dendritic spine morphology and neurodevelopment.

Conclusion -- Outlook
=====================

The genomic and gene-expression "boom" of the early 00's, bolstered by the advent of technologies to measure transcriptional changes (micro-array, RNA/exome/whole genome next generation sequencing) has placed a focus on transcription as the key step in the gene-expression pathway underlying the pathophysiology of neuropsychiatric disorders ([@B67]; [@B64]; [@B93]). Thus, the regulatory mechanisms of protein synthesis have not received much attention, while translational control and investigation of the translatome has not become part of large consortia mainly due to the lack of accessible genome-wide methodologies. The onset of translatome profiling will change this trend and important mechanistic data will surface in the coming years ([@B55], [@B56]). Thirty-nine years after its discovery, eIF4E still poses an enigma as to the identity of the mRNAs it controls and the precise regulatory mechanisms it participates in during different stages of development and in different cell-types of the brain. Understanding the role of cap-dependent translation in the brain will facilitate the adaptation of the already existing compendium of biochemical/genetic models and pharmacological approaches to modulate translation ([@B120]; [@B80], [@B81]), for the treatment of neuropsychiatric disorders.
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